215 related articles for article (PubMed ID: 22787067)
1. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
[TBL] [Abstract][Full Text] [Related]
2. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
4. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
6. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
7. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
[No Abstract] [Full Text] [Related]
8. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
[TBL] [Abstract][Full Text] [Related]
9. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Joseph P; Pais P; Dans AL; Bosch J; Xavier D; Lopez-Jaramillo P; Yusoff K; Santoso A; Talukder S; Gamra H; Yeates K; Lopez PC; Tyrwhitt J; Gao P; Teo K; Yusuf S;
Am Heart J; 2018 Dec; 206():72-79. PubMed ID: 30342297
[TBL] [Abstract][Full Text] [Related]
10. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
11. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
[TBL] [Abstract][Full Text] [Related]
12. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
13. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.
Mariani J; Rosende A; De Abreu M; Gonzalez Villa Monte G; D'Imperio H; Antonietti L; Lemonnier G; de Bonis A; Tajer C
Ther Adv Cardiovasc Dis; 2020; 14():1753944720912071. PubMed ID: 32186246
[TBL] [Abstract][Full Text] [Related]
14. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Grimm R; Malik M; Yunis C; Sutradhar S; Kursun A;
Vasc Health Risk Manag; 2010 May; 6():261-71. PubMed ID: 20479948
[TBL] [Abstract][Full Text] [Related]
16. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
17. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
[TBL] [Abstract][Full Text] [Related]
18. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
19. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
[TBL] [Abstract][Full Text] [Related]
20. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]